Loading
MAO-A is an enzyme best known for breaking down serotonin and other signalling chemicals in the brain; medicines called MAO inhibitors, used for some neurological disorders, block it. Aggressive prostate cancers carry more of it, and a MAO-A inhibitor designed to stay out of the brain is in an early prostate cancer trial.
MAOA (chromosome Xp11.3) is a mitochondrial enzyme that breaks down amine neurotransmitters such as serotonin, producing hydrogen peroxide (UniProt P21397). A 2014 Journal of Clinical Investigation study reported that high-grade, aggressive prostate tumours express more MAOA, that MAOA drove epithelial-to-mesenchymal transition and stabilised HIF1-alpha through reactive oxygen species, and that knocking it down reduced or eliminated prostate tumour growth and metastasis in mouse models (Wu et al., doi:10.1172/JCI70982). In OnCo, ITR-251 is a reversible MAO-A inhibitor with limited ability to cross the blood-brain barrier, in a phase 1 trial in metastatic castration-resistant prostate cancer.
In plain words · MAO-A is an enzyme best known for breaking down serotonin and other signalling chemicals in the brain; medicines called MAO inhibitors, used for some neurological disorders, block it. Aggressive prostate cancers carry more of it, and a MAO-A inhibitor designed to stay out of the brain is in an early prostate cancer trial.
MAO-A is an enzyme best known for breaking down serotonin and other signalling chemicals in the brain; medicines called MAO inhibitors, used for some neurological disorders, block it. Aggressive prostate cancers carry more of it, and a MAO-A inhibitor designed to stay out of the brain is in an early prostate cancer trial.
Amine oxidase that breaks down neuroactive and vasoactive amines and prefers serotonin as substrate (UniProt P21397).
1 product aims at MAO-A (MAOA): small molecules. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Amine oxidase that breaks down neuroactive and vasoactive amines and prefers serotonin as substrate (UniProt P21397).
ITR-251 is an experimental small molecule from Iteria Biopharma, in phase 1 trials for metastatic castration-resistant prostate cancer and advanced solid tumours.
Query for this target: (TITLE:"MAO-A" OR ABSTRACT:"MAO-A" OR TITLE:"MAOA" OR ABSTRACT:"MAOA" OR TITLE:"monoamine oxidase A" OR ABSTRACT:"monoamine oxidase A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MAO-A (MAOA), not a curated reading list.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline-gap-target.
Shares ITR-251, Metastatic castration-resistant prostate cancer.
Shares ITR-251, Metastatic castration-resistant prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/